These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 34921019)

  • 1. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer.
    Jin Y; Chen Y; Tang H; Hu X; Hubert SM; Li Q; Su D; Xu H; Fan Y; Yu X; Chen Q; Liu J; Hong W; Xu Y; Deng H; Zhu D; Li P; Gong Y; Xia X; Gay CM; Zhang J; Chen M
    Clin Cancer Res; 2022 Feb; 28(3):526-539. PubMed ID: 34921019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K/Akt/mTOR signaling orchestrates the phenotypic transition and chemo-resistance of small cell lung cancer.
    Li X; Li C; Guo C; Zhao Q; Cao J; Huang HY; Yue M; Xue Y; Jin Y; Hu L; Ji H
    J Genet Genomics; 2021 Jul; 48(7):640-651. PubMed ID: 34167917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.
    Umemura S; Mimaki S; Makinoshima H; Tada S; Ishii G; Ohmatsu H; Niho S; Yoh K; Matsumoto S; Takahashi A; Morise M; Nakamura Y; Ochiai A; Nagai K; Iwakawa R; Kohno T; Yokota J; Ohe Y; Esumi H; Tsuchihara K; Goto K
    J Thorac Oncol; 2014 Sep; 9(9):1324-31. PubMed ID: 25122428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
    Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
    Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1.
    Chen R; Li D; Zheng M; Chen B; Wei T; Wang Y; Li M; Huang W; Tong Q; Wang Q; Zhu Y; Fang W; Guo L; Fang S
    J Cell Mol Med; 2020 Feb; 24(3):2123-2134. PubMed ID: 31957179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma.
    Makinoshima H; Umemura S; Suzuki A; Nakanishi H; Maruyama A; Udagawa H; Mimaki S; Matsumoto S; Niho S; Ishii G; Tsuboi M; Ochiai A; Esumi H; Sasaki T; Goto K; Tsuchihara K
    Cancer Res; 2018 May; 78(9):2179-2190. PubMed ID: 29490947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
    Udagawa H; Umemura S; Murakami I; Mimaki S; Makinoshima H; Ishii G; Miyoshi T; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuchihara K; Goto K
    Lung Cancer; 2018 Dec; 126():182-188. PubMed ID: 30527185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosomal lncRNA FOXD3-AS1 upregulates ELAVL1 expression and activates PI3K/Akt pathway to enhance lung cancer cell proliferation, invasion, and 5-fluorouracil resistance.
    Mao G; Mu Z; Wu DA
    Acta Biochim Biophys Sin (Shanghai); 2021 Nov; 53(11):1484-1494. PubMed ID: 34605863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway.
    Tripathi SC; Fahrmann JF; Celiktas M; Aguilar M; Marini KD; Jolly MK; Katayama H; Wang H; Murage EN; Dennison JB; Watkins DN; Levine H; Ostrin EJ; Taguchi A; Hanash SM
    Cancer Res; 2017 Aug; 77(16):4414-4425. PubMed ID: 28646020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
    Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
    PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer.
    Wagner AH; Devarakonda S; Skidmore ZL; Krysiak K; Ramu A; Trani L; Kunisaki J; Masood A; Waqar SN; Spies NC; Morgensztern D; Waligorski J; Ponce J; Fulton RS; Maggi LB; Weber JD; Watson MA; O'Conor CJ; Ritter JH; Olsen RR; Cheng H; Mukhopadhyay A; Can I; Cessna MH; Oliver TG; Mardis ER; Wilson RK; Griffith M; Griffith OL; Govindan R
    Nat Commun; 2018 Sep; 9(1):3787. PubMed ID: 30224629
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Li M; Lin A; Luo P; Shen W; Xiao D; Gou L; Zhang J; Guo L
    Aging (Albany NY); 2020 Jan; 12(2):1285-1303. PubMed ID: 31959735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance of human small cell lung cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Yu XS; Du J; Fan YJ; Liu FJ; Cao LL; Liang N; Xu DG; Zhang JD
    Oncotarget; 2016 Nov; 7(47):76827-76839. PubMed ID: 27765907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
    Li H; Wang H; Deng K; Han W; Hong B; Lin W
    Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes.
    Jiang W; Zhang W; Wu L; Liu L; Men Y; Wang J; Liang J; Hui Z; Zhou Z; Bi N; Wang L
    Biomed Res Int; 2017; 2017():6501385. PubMed ID: 28280736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
    Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
    Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol inhibits viability and induces apoptosis in the small‑cell lung cancer H446 cell line via the PI3K/Akt/c‑Myc pathway.
    Li W; Li C; Ma L; Jin F
    Oncol Rep; 2020 Nov; 44(5):1821-1830. PubMed ID: 32901891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations.
    Krencz I; Sztankovics D; Danko T; Sebestyen A; Khoor A
    Cancer Metastasis Rev; 2021 Dec; 40(4):1141-1157. PubMed ID: 34958428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
    Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
    Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.